1. Home
  2. ORLA vs AMRX Comparison

ORLA vs AMRX Comparison

Compare ORLA & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orla Mining Ltd.

ORLA

Orla Mining Ltd.

HOLD

Current Price

$9.79

Market Cap

4.5B

ML Signal

HOLD

Logo Amneal Pharmaceuticals Inc.

AMRX

Amneal Pharmaceuticals Inc.

HOLD

Current Price

$16.96

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORLA
AMRX
Founded
2007
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.0B
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
ORLA
AMRX
Price
$9.79
$16.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$21.00
$15.60
AVG Volume (30 Days)
3.3M
2.2M
Earning Date
05-08-2026
05-01-2026
Dividend Yield
0.12%
N/A
EPS Growth
N/A
157.89
EPS
N/A
0.19
Revenue
N/A
N/A
Revenue This Year
$63.44
$4.48
Revenue Next Year
N/A
$7.13
P/E Ratio
$107.37
$89.53
Revenue Growth
N/A
N/A
52 Week Low
$9.15
$7.67
52 Week High
$21.98
$17.86

Technical Indicators

Market Signals
Indicator
ORLA
AMRX
Relative Strength Index (RSI) 40.55 68.98
Support Level $9.62 $12.46
Resistance Level $10.50 $17.86
Average True Range (ATR) 0.41 0.54
MACD 0.10 -0.13
Stochastic Oscillator 46.10 54.92

Price Performance

Historical Comparison
ORLA
AMRX

About ORLA Orla Mining Ltd.

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects: the Camino Rojo gold and silver project in Zacatecas State, the Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: